Best Immunotherapy Companies in Japan
The 33 best Immunotherapy companies in Japan in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Noile-Immune Biotech.
Our analysis of 50 Immunotherapy companies
$8.8b in tracked funding; 69% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Immunotherapy companies in Japan
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Noile-Immune Biotech Developer of next-gen CAR-T immunotherapy platform for solid tumors | $22M | 67 mo ago | Public | 28 | — | Apache HTTP ServerAmazon Web ServicesUmami+7 | 132 patents Engineered CAR-T cells targeting mesothelin with IL‑7/CCL19 cytokine support | — |
| 2 | UMN Pharma Developing vaccines for influenza | $20M | 236 mo ago | Public | 42 | — | NginxGoogle Font APISakura Internet+3 | — | — |
| 3 | Thyas Developer of induced pluripotent stem cells technology to treat cancer | $18M | 56 mo ago | Series B | 4 | — | — | 39 patents iPSC-derived engineered T‑cell production and cell‑bank platforms for immunotherapy | — |
| 4 | Gaia Biomedicine Provider of regenerative medicine for treating cancer | $13M | 15 mo ago | Series D | — | Yoshikazu Yoneman Founder | WordPressMySQLPHP+15 | 111 patents Engineered NK cell immunotherapies and cytokine-anchored cell manufacturing platforms | — |
| 5 | Tella Dendritic cell vaccine for WT1 peptide | $9M | 111 mo ago | Deadpooled | 30 | — | WordPressMySQLPHP+15 | 34 patents Cellular immunotherapy using gene‑edited T/NK cells targeting WT1 and survivin cancer antigens | — |
| 6 | Optieum Biotechnologies Developer of chimeric antigen receptor T-cell therapies for cancer | $8M | 21 mo ago | Series A | 4 | Toshiki Ochi Co-Founder | — | 2 patents Engineered CAR-T and checkpoint antibody therapeutics for cancer immunotherapy | — |
| 7 | RegCell Regulatory T cells based therapies for the treatment of autoimmune diseases | $7M | 113 mo ago | Series A | 5 | Shimon Sakaguchi Founder | — | 31 patents Engineered regulatory T‑cell therapies and related pharmaceutical formulations for immune modulation | — |
| 8 | AccuRna Provider of nucleic acid therapeutics using drug delivery platform | $5M | 105 mo ago | Seed | 23 | Shiro Akinaga CEO | — | 10 patents Polyion complex platforms for efficient mRNA delivery and protein expression enhancement | — |
| 9 | NB Health Laboratory Japanese biopharma developing MAbs therapeutics targeting GCPRs in respiratory diseases, chronic inflammation… | $3M | 54 mo ago | Series C | — | Kiyoshi Takayama Founder | WordPress Block EditorWordPressMySQL+14 | 38 patents Antibody and nucleic acid therapeutics, recombinant cell production, and biotech drug formulation | — |
| 10 | Vasculead Developer of combination therapy and peptide vaccine for cancer | $3M | 105 mo ago | Seed | — | Yosuke Suzuki Founder & CEO | — | 9 patents Peptide therapeutics targeting PSF1 protein for cancer treatment | — |
| 11 | OMR Developer of antibodies for the treatment of various diseases | $3M | 114 mo ago | Seed | 12 | Yasufumi Murakami Founder | — | — | — |
| 12 | HISHOH Biopharma Developer of immunotherapy for allergies | $2M | 62 mo ago | Seed | — | Naoki Sakurai CEO | — | — | — |
| 13 | Immunorock Developer of immunotherapies for the treatment of cancer and infectious diseases | $1M | 10 mo ago | Seed | — | Toshiro Shirakawa CEO | — | — | — |
| 14 | TKG Therapeutics Developer of therapeutics for cancer patients | $1M | 33 mo ago | Seed | — | Masaaki Matsui CEO | — | 2 patents Synthetic methods for therapeutic oligonucleotides and nucleic acid assembly | — |
Top 12 Immunotherapy companies in Japan
#1
Series D · Fukuoka, Fukuoka · founded 2015$13.2Mraised▾
GAIA Biomed provides regenerative medicine for treating cancer. It develops a new group of cell products (products such as regenerative medicine) for the treatment of cancer.
- Jul 2025Series D$13.2M
#2
Seed · Kobe, Hyogo · founded 2021$1Mraised▾
Developer of immunotherapies for the treatment of cancer and infectious diseases. The company is focused on developing a cancer immunotherapy drug using an innovative oral vaccine platform technology which include B440 WT1 oral cancer vaccine and the BCOV332 oral Covid vaccine.
- Dec 2025Seed$315.4K
- Jul 2025Seed$1.2M
- Apr 2024Seed$292.5K
- Jul 2023Seed$747.8K
#3
Series A · Ehime · founded 2020 · 4 employees$8.4Mraised▾
Developer of chimeric antigen receptor T-cell therapies for cancer. The company has developed Eumbody System technology that enables to develop and detect scFv-based product candidates for therapeutic purposes. This technology has the potential to develop T-cell therapies for cancer, autoimmune and infectious diseases.
- Jan 2025Series A$8.4M
#4
Series B · Kyoto, Kyoto · founded 2015 · 4 employees$18.2Mraised▾
Thyas is involved in developing iPSC technology to treat cancer. They have developed autologous adoptive immunotherapy with induced pluripotent stem cells (iPSC)-derived killer T cells. Their technology helps to convert the exhausted killer T immune cells to stem cells to produce new T cells which target cancer and other chronic infections.
- Feb 2022Series B$18.2M
#5
Public · Tokyo, Tokyo · founded 2015 · 28 employees$21.9Mraised▾
Developer of next-gen CART-T immunotherapy platform for solid tumors. The company is developing CAR-T therapies for hematological cancers. To improve the efficacy of CAR-T cells in solid tumors, the company has developed an enhanced CAR-T platforms.
- Mar 2021Series C$21.9M
- Mar 2020Series B—
#6
Seed · Bunkyo, Tokyo · founded 2022$1Mraised▾
Developer of therapeutics for cancer patients. It offers Oncolytic Hairpin DNA Pair technology for development of immune-activating therapy that targets cancer cells with high miRNA expression. It induces innate immune activation, that targets the cGAS-STING pathway to kill cancer cells.
- Jan 2024Seed$1M
#7
Public · Yokohama, Kanagawa Prefecture · founded 2004 · 42 employees$20Mraised▾
UMN Pharma researches, develops, manufactures and distributes bio-pharmaceutical products. It is currently focussed on developing vaccines for influenza market. It is developing its lead candidate UMN-0502 in collaboration with the Astellas Pharma and is planning to expand it to US vaccine market. It is also working on the commercialization of its other vaccine candidate UMN-2002 and is planning to develop new vaccine candidates by further leveraging BEVS platform.
- Feb 2007Series C$18.9M
- Oct 2005Series B$1.1M
#8
Series C · Sapporo, Hokkaido · founded 2006$3.3Mraised▾
NB Health Laboratory is a Japanese biopharma developing MAbs therapeutics targeting GCPRs in respiratory diseases, chronic inflammation, and central nervous system disorders. It currently has 5 different drug candidates in preclinical stages - for indications such as cancer, autoimmune disease, lung fibrosis, kidney fibrosis, sinusitis, COPD, etc.
- Apr 2022Series C$7.5M
- May 2018Series A$3.3M
#9
Deadpooled · Tokyo, Tokyo · founded 2004 · 30 employees$8.9Mraised▾
Tella is a Japanese, early-stage biopharma developing dendritic-cell vaccines. Tella has the exclusive license for the cancer marker WT1 peptide and its use in Dendritic Vaccines. The company has developed the treatment for 11410 patients as on Jun.2017. The therapy is not covered by public health insurance in Japan.
- Jul 2017Post IPO$8.9M
#10
Series A · Fujisawa, Kanagawa Prefecture · founded 2016 · 5 employees$7Mraised▾
RegCell is developing regulatory T cells based therapies for the treatment of Autoimmune diseases. The company research protocol involves regulating control T cells to proliferate and activate them outside the body and then return them to patients. The company has early stage preclinical stage programs for rheumatism and acute immune rejection after organ transplantation.
- May 2017Series A$1.5M
- Series A$5.5M
#11
Seed · Chuo, Tokyo · founded 2021$2.3Mraised▾
Developer of immunotherapy for allergies. It offers HSO-001 a potent agonist for Toll-like receptor 4 recognises allergens and induces immune responses. It also provide Sublingual immunotherapy which is a type of allergen immunotherapy and is a treatment for allergies that involves administering a small amount of allergen under the tongue.
- Aug 2021Seed$2.3M
#12
Seed · Bunkyo, Tokyo · founded 2015 · 23 employees$5.1Mraised▾
Provider of nucleic acid therapeutics using drug delivery platform. The company develops nucleic acid medicine from RNA, miRNA, siRNA by its proprietary drug delivery technology platform. It has two drug delivery systems namely, uni Poly Ion Complex (uPIC) for short-chain RNA for nucleic acid drug development and Polyplex micelle for long-chain RNA for the mRNA therapeutics.
- Jan 2018Seed$5.1M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Immunotherapy coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.